Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Icosavax, Inc. ICVX
$8.09
-$0.2 (-2.41%)
На 18:04, 12 мая 2023
+233.75%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
301109587.00000000
-
week52high
16.45
-
week52low
2.28
-
Revenue
0
-
P/E TTM
-3
-
Beta
0.00000000
-
EPS
-2.87000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 04:00
Описание компании
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| William Blair | Outperform | 23 авг 2021 г. | |
| Jefferies | Buy | 23 авг 2021 г. | |
| Evercore ISI Group | Outperform | 23 авг 2021 г. | |
| Cowen & Co. | Outperform | 23 авг 2021 г. | |
| Oppenheimer | Outperform | 04 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cearley Cassia | D | 2511 | 25102 | 30 янв 2023 г. |
| Cearley Cassia | A | 156840 | 25102 | 30 янв 2023 г. |
| Simpson Adam K. | D | 427927 | 10678 | 25 янв 2023 г. |
| Simpson Adam K. | D | 31132 | 2395 | 25 янв 2023 г. |
| Simpson Adam K. | A | 252547 | 10678 | 25 янв 2023 г. |
| Simpson Adam K. | A | 241869 | 2395 | 25 янв 2023 г. |
| Simpson Adam K. | D | 33527 | 14369 | 23 дек 2022 г. |
| Simpson Adam K. | A | 239474 | 14369 | 23 дек 2022 г. |
| Simpson Adam K. | D | 225105 | 66764 | 21 дек 2022 г. |
| Holtzman Douglas | D | 2792 | 19648 | 15 дек 2022 г. |
Новостная лента
Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study
Zacks Investment Research
15 дек 2022 г. в 20:18
Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.
Icosavax, Inc. (ICVX) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
14 ноя 2022 г. в 21:03
Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 3.51% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Icosavax to Participate in in Upcoming Investor Conferences
GlobeNewsWire
08 ноя 2022 г. в 08:00
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the following investor conferences:
Icosavax, Inc. (ICVX) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
15 авг 2022 г. в 18:48
Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?